Tamtuvetmab
Modify Date: 2025-08-26 18:50:54
Tamtuvetmab structure
|
Common Name | Tamtuvetmab | ||
|---|---|---|---|---|
| CAS Number | 1608122-71-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TamtuvetmabTamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary[1][2]. |
| Name | Tamtuvetmab |
|---|
| Description | Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary[1][2]. |
|---|---|
| Related Catalog | |
| Target |
CD52[1] |
| In Vivo | Tamtuvetmab (5 mg/mL, 7.5-30 mL; i.v.; 15-30 min) has in vivo efficacy in dogs with naïve T-cell lymphoma (LSA), but resulting in vomiting, weight loss, diarrhoea, lethargy, decreased appetite and anorexia[1]. Animal Model: T-cell LSA Model in Dog[1] Dosage: 5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL Administration: Intravenous injection; 15-30 min Result: Showed in vivo efficacy with severe side effect. |
| References |
| No Any Chemical & Physical Properties |